132 related articles for article (PubMed ID: 2537769)
1. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study.
Friedman AJ
Fertil Steril; 1989 Mar; 51(3):526-8. PubMed ID: 2537769
[TBL] [Abstract][Full Text] [Related]
2. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy.
Barbieri RL
Am J Obstet Gynecol; 1990 Feb; 162(2):593-5. PubMed ID: 2137979
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri.
Friedman AJ; Barbieri RL; Doubilet PM; Fine C; Schiff I
Fertil Steril; 1988 Mar; 49(3):404-9. PubMed ID: 2963759
[TBL] [Abstract][Full Text] [Related]
5. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist.
Friedman AJ; Barbieri RL; Benacerraf BR; Schiff I
Fertil Steril; 1987 Oct; 48(4):560-4. PubMed ID: 3115833
[TBL] [Abstract][Full Text] [Related]
6. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri.
Scialli AR; Jestila KJ
Fertil Steril; 1995 Aug; 64(2):313-20. PubMed ID: 7615109
[TBL] [Abstract][Full Text] [Related]
7. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging of leiomyomata uteri: assessing therapy with the gonadotropin-releasing hormone agonist leuprolide.
Lubich LM; Alderman MG; Ros PR
Magn Reson Imaging; 1991; 9(3):331-4. PubMed ID: 1908932
[TBL] [Abstract][Full Text] [Related]
9. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years.
Friedman AJ; Daly M; Juneau-Norcross M; Gleason R; Rein MS; LeBoff M
Hum Reprod; 1994 Sep; 9(9):1618-25. PubMed ID: 7836510
[TBL] [Abstract][Full Text] [Related]
10. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group.
Friedman AJ; Hoffman DI; Comite F; Browneller RW; Miller JD
Obstet Gynecol; 1991 May; 77(5):720-5. PubMed ID: 1901638
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata.
Palomba S; Affinito P; Tommaselli GA; Nappi C
Fertil Steril; 1998 Jul; 70(1):111-8. PubMed ID: 9660431
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
Friedman AJ; Lobel SM; Rein MS; Barbieri RL
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
[TBL] [Abstract][Full Text] [Related]
13. Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women.
Clisham PR; de Ziegler D; Lozano K; Judd HL
Obstet Gynecol; 1991 Feb; 77(2):241-6. PubMed ID: 1846438
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
Carr BR; Marshburn PB; Weatherall PT; Bradshaw KD; Breslau NA; Byrd W; Roark M; Steinkampf MP
J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313
[TBL] [Abstract][Full Text] [Related]
15. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
[TBL] [Abstract][Full Text] [Related]
16. [Short-term therapy of uterine fibromyomatosis with GN-Rh analog].
Massacesi M; Milkowski M; Gianfranceschi C; Massacesi L
Minerva Ginecol; 1992 Dec; 44(12):641-4. PubMed ID: 1491772
[TBL] [Abstract][Full Text] [Related]
17. Vaginal hemorrhage associated with degenerating submucous leiomyomata during leuprolide acetate treatment.
Friedman AJ
Fertil Steril; 1989 Jul; 52(1):152-4. PubMed ID: 2501108
[TBL] [Abstract][Full Text] [Related]
18. Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo.
Friedman AJ; Rein MS; Pandian MR; Barbieri RL
Fertil Steril; 1990 Feb; 53(2):250-3. PubMed ID: 2105242
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata.
Friedman AJ; Harrison-Atlas D; Barbieri RL; Benacerraf B; Gleason R; Schiff I
Fertil Steril; 1989 Feb; 51(2):251-6. PubMed ID: 2492232
[TBL] [Abstract][Full Text] [Related]
20. Histopathological changes in leiomyomata treated with leuprolide acetate.
Upadhyaya NB; Doody MC; Googe PB
Fertil Steril; 1990 Nov; 54(5):811-4. PubMed ID: 2121550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
